MX2023000004A - Formulaciones para promover la hidratacion y metodos de uso de las mismas. - Google Patents

Formulaciones para promover la hidratacion y metodos de uso de las mismas.

Info

Publication number
MX2023000004A
MX2023000004A MX2023000004A MX2023000004A MX2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A MX 2023000004 A MX2023000004 A MX 2023000004A
Authority
MX
Mexico
Prior art keywords
barrier function
intestinal barrier
formulations
need
hydration
Prior art date
Application number
MX2023000004A
Other languages
English (en)
Spanish (es)
Inventor
Sadasivan Vidyasagar
Astrid Grosche
Stephen Gatto
Xiaodong Xu
Shanshan Lin
Robert Kenefick
Samuel Cheuvront
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2023000004A publication Critical patent/MX2023000004A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2023000004A 2020-07-02 2021-07-01 Formulaciones para promover la hidratacion y metodos de uso de las mismas. MX2023000004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047300P 2020-07-02 2020-07-02
PCT/US2021/040090 WO2022006397A1 (en) 2020-07-02 2021-07-01 Formulations for promoting hydration and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023000004A true MX2023000004A (es) 2023-03-06

Family

ID=79314908

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000004A MX2023000004A (es) 2020-07-02 2021-07-01 Formulaciones para promover la hidratacion y metodos de uso de las mismas.

Country Status (11)

Country Link
US (2) US12357600B2 (https=)
EP (1) EP4175662A4 (https=)
JP (1) JP2023533617A (https=)
KR (1) KR20230047371A (https=)
CN (1) CN116194136A (https=)
AU (1) AU2021300188A1 (https=)
BR (1) BR112022027124A2 (https=)
CA (1) CA3184691A1 (https=)
IL (1) IL299488A (https=)
MX (1) MX2023000004A (https=)
WO (1) WO2022006397A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916903A1 (de) * 1989-05-24 1991-02-28 Leopold Pharma Gmbh Waessrige zusammensetzung fuer die parenterale ernaehrung
JP2002275059A (ja) * 2001-03-15 2002-09-25 Inst Of Physical & Chemical Res 腎機能障害改善用アミノ酸組成物
WO2010017403A2 (en) * 2008-08-06 2010-02-11 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
CN102170876B (zh) * 2008-10-06 2013-12-04 株式会社明治 含有氨基酸组合物作为有效成分的耐力提高剂、抗疲劳剂或疲劳恢复剂
KR101758424B1 (ko) * 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
HK1204290A1 (en) * 2012-02-08 2015-11-13 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
EP3459540A1 (en) * 2014-11-24 2019-03-27 Entrinsic Health Solutions, Inc. Amino acid compositions for the treatment of symptoms of disease
EP3522882A4 (en) * 2016-10-04 2020-06-24 The University of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND USES THEREOF
CN109218470B (zh) * 2017-07-05 2021-08-24 中兴通讯股份有限公司 移动终端及其控制方法
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA

Also Published As

Publication number Publication date
US12357600B2 (en) 2025-07-15
US20230149335A1 (en) 2023-05-18
US20250367154A1 (en) 2025-12-04
CA3184691A1 (en) 2022-12-30
WO2022006397A1 (en) 2022-01-06
KR20230047371A (ko) 2023-04-07
AU2021300188A1 (en) 2023-02-02
EP4175662A1 (en) 2023-05-10
JP2023533617A (ja) 2023-08-03
CN116194136A (zh) 2023-05-30
BR112022027124A2 (pt) 2023-03-07
EP4175662A4 (en) 2024-07-17
IL299488A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2020010130A (es) Formulacion y metodo de preparacion.
UY29377A1 (es) Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos.
ES2080837T3 (es) Tratamiento de estados y enfermedades.
SG162788A1 (en) Self-buffering protein formulations
EP4477267A3 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
UY39083A (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
MX2023000004A (es) Formulaciones para promover la hidratacion y metodos de uso de las mismas.
WO2023141176A3 (en) Neutralizing antibodies and antigen-binding fragments thereof against omicron and other coronavirus variants, and methods of making and using the same
CL2023000099A1 (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular
WO2023081194A3 (en) Methods for treating alzheimer's disease
CL2025001617A1 (es) Métodos para tratar la enfermedad de pompe de inicio infantil en pacientes pediátricos
Brazzelli et al. Bleomycin-induced flagellate dermatitis: report of four paediatric cases.
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
TUFFANELLI A clinical trial with dimethyl sulfoxide in scleroderma
BR112022010458A2 (pt) Formulação pediátrica de liberação imediata do abridor de canais de potássio ezogabina
WO2021050564A3 (en) Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders
MX2022002451A (es) Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.
Levy et al. Tinea versicolor associated with etanercept therapy
Acharya et al. Aloe Vera: A multifaceted ayurvedic herb used in palliative care of oral cancer patients
EA202192459A1 (ru) Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
Srinivasa et al. Intralesional BCG: an answer to recalcitrant warts
MX2025005174A (es) Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial